Neumora therapeutics inc
NMRA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
NMRA 近期報酬表現
0.11%
Neumora therapeutics inc
2.06%
同產業平均
-0.34%
S&P500
與 NMRA 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
SVRA | Savara inc | 3 分 | 3 分 | 3 分 | 3 分 | 1 分 | |
ABUS | Arbutus biopharma corp | 4 分 | 3 分 | 3 分 | 3 分 | 1 分 | |
FOLD | Amicus therapeutics, inc | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
TXG | 10x genomics inc | 2 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
RARE | Ultragenyx pharmaceutical inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 |
- SVRA Savara inc價值 3 分趨勢 3 分波段 3 分籌碼 3 分股利 1 分查看更多
NMRA 公司資訊
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.